Exact Sciences Corporation (EXAS)
Market Cap | 11.98B |
Revenue (ttm) | 2.08B |
Net Income (ttm) | -623.51M |
Shares Out | 179.23M |
EPS (ttm) | -3.54 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 151,987 |
Open | 67.61 |
Previous Close | 67.11 |
Day's Range | 66.59 - 67.88 |
52-Week Range | 29.27 - 76.94 |
Beta | 1.42 |
Analysts | Buy |
Price Target | 77.76 (+16.3%) |
Earnings Date | Apr 25, 2023 |
About EXAS
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX... [Read more]
Financial Performance
In 2022, Exact Sciences's revenue was $2.08 billion, an increase of 17.95% compared to the previous year's $1.77 billion. Losses were -$623.51 million, 4.68% more than in 2021.
Financial StatementsAnalyst Forecast
According to 26 analysts, the average rating for EXAS stock is "Buy." The 12-month stock price forecast is $77.76, which is an increase of 16.30% from the latest price.
News

3 Stocks With Superior Potential for Super-Sized Gains in 2023
Stocks with potential are probably not everyone's cup of tea right now. With talks of an impending recession, everyone is looking for safer options.

Cathie Wood Is Betting Big on These 5 AI Stocks
Love it or hate it, tech investing is back on the menu in 2023. As a result, Cathie Wood's back in the limelight.

Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes
MADISON, Wis. , Feb. 23, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on February 23, 202...

Exact Sciences (EXAS) Q4 Earnings Top Estimates, Margin Falls
Robust revenues from the Screening and Precision Oncology segments contributed to the Exact Sciences (EXAS) Q4 top line.

Exact Sciences to participate in March investor conferences
MADISON, Wis. , Feb. 22, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate...

Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates
Exact Sciences (EXAS) delivered earnings and revenue surprises of 20% and 6.49%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Exact Sciences Announces Fourth Quarter 2022 Results
Reports record revenue, expects revenue of $2,265-2,315 million and positive adjusted EBITDA for full year 2023 Fourth quarter and 2022 highlights Total fourth quarter revenue of $553 million, an inc...

5 Large-Cap Stocks Set to Beat on Q4 Earnings This Week
The following five large-cap stocks are set to beat Q4 earnings estimates this week. These are: TECK, LECO, NI, EXAS and GFL.

Why Earnings Season Could Be Great for Exact Sciences (EXAS)
Exact Sciences (EXAS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Exact Sciences (EXAS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Exact Sciences (EXAS) Recently Broke Out Above the 20-Day Moving Average
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?

3 MedTech Stocks Likely to Beat Estimates This Earnings Season
MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EXAS, MDT and IART are poised ahead of their earnings releases.

Exact Sciences (EXAS) to Post Q4 Earnings: What's in Store?
Continued increase in Cologuard volume is likely to have benefited Exact Sciences (EXAS) Q4 performance.

Exact Sciences Launches OncoExTra™ Cancer Therapy Selection Test in the U.S.
Test Identifies Tumor DNA and RNA Alterations to Help Guide Personalized Treatments for Patients Based on Their Cancer MADISON, Wis. , Feb. 7, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS),...

Is Biotech Immunocore About To Make A 25% Price Move?
The industry is home to some large-cap heavyweights, including Amgen Inc. (NASDAQ: AMGN), Gilead Sciences Inc. (NASDAQ: GILD), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Vertex Pharmaceuticals Inc...

Cathie Wood Is Doubling Down on This Hidden-Gem Artificial Intelligence Stock
In November 2021, Cathie Wood described artificial intelligence as the “next big frontier” of the tech sector. Roughly a year later, OpenAI released advanced chatbot ChatGPT, and almost overnight, the...

Exact Sciences schedules fourth quarter 2022 earnings call
MADISON, Wis. , Feb. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fou...

Has Exact Sciences (EXAS) Outpaced Other Medical Stocks This Year?
Here is how Exact Sciences (EXAS) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.

Cathie Wood Is Buying These Stocks, Should You?
Cathie Wood is known for her deep understanding of tech companies and for holding aggressive long positions in her tech funds. Let's look at what she's buying.

3 Top Stocks Already up More Than 20% In 2023
While inflation remains the market's primary concern, these three stocks have gotten off to a great start in 2023, already up more than 20% year-to-date. Can the strength continue?

Here's Why Investors Should Buy Exact Sciences (EXAS) Stock
Investors are optimistic about Exact Sciences (EXAS) on continued strength across the Screening and Precision Oncology businesses.

Cathie Wood Makes This Molecular Diagnostics Company Top Holding Of Ark Invest's Flagship Fund, Catapulting Past Zoom, Tesla
Shares of Exact Sciences, Inc. EXAS have been on a tear, having gained over 27% in two sessions this week.

Exact Sciences Corp Stock Price Is Trending Up Here's Why
Exact Science's stock price is shooting higher this week amid posting upward revisions for its revenue and earnings estimates for this quarter.

Cathie Wood's Top 5 Stocks See Abysmal Year in 2022
As we head into a new year, investors are taking a look at their portfolios to determine which stocks were winners and losers in 2022.

Strength Seen in Exact Sciences (EXAS): Can Its 24.7% Jump Turn into More Strength?
Exact Sciences (EXAS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price incre...